Jomil

Tamsulosin Hydrochloride and Solifenacin Succinate, the active ingredient in Jomil, is an Alpha‑1 adrenergic antagonist and Muscarinic (M3) receptor antagonist presented as an oral tablet for oral use. The combination therapy targets both prostate smooth‑muscle tone and bladder detrusor overactivity, providing a comprehensive approach to urinary symptom management. It treats benign prostatic hyperplasia (BPH) and overactive bladder (OAB) symptoms in adult patients.

GNH USA supplies Jomil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance and regulatory compliance across all markets.

Jomil acts on the lower urinary tract to relieve symptoms associated with benign prostatic hyperplasia and overactive bladder. - Benign prostatic hyperplasia (BPH): improves urinary flow and reduces bladder outlet obstruction. - Overactive bladder (OAB): decreases urgency, frequency and incontinence episodes. - Lower urinary tract symptoms (LUTS): provides overall symptom relief and better quality of life. - Urinary retention secondary to BPH: facilitates bladder emptying.

Jomil may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially on standing. - Dry mouth: reduced salivation leading to throat discomfort. - Constipation: slowed gastrointestinal transit. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Priapism: prolonged painful erection requiring urgent care. - Severe hypotension: marked drop in blood pressure, may cause fainting. - Allergic reactions: rash, swelling, or anaphylaxis in rare cases. - QT interval prolongation: potential cardiac rhythm disturbance.

Before prescribing Jomil, consider the following precautions to ensure safe use. - Renal impairment: assess kidney function and adjust therapy if necessary. - Hepatic impairment: use with caution in patients with liver disease. - Cardiovascular disease: monitor blood pressure due to possible hypotensive effect. - History of urinary retention: evaluate risk before initiating therapy. - Concomitant anticholinergic drugs: increased risk of dry mouth and constipation. - Store at ambient temperature: keep in the original pack, protect from moisture.

Jomil can interact with other medicines; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase tamsulosin plasma levels, raising hypotension risk. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce solifenacin exposure, decreasing efficacy. - Other anticholinergic agents (e.g., diphenhydramine): additive anticholinergic effects leading to severe dryness. - Alpha‑adrenergic blockers combined with hypotensive drugs (e.g., antihypertensives): risk of marked blood pressure drop.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance orthostatic hypotension when used with tamsulosin. - Warfarin: solifenacin may potentiate anticoagulant effect, requiring INR monitoring. - Other bladder agents (e.g., mirabegron): possible pharmacodynamic interaction affecting urinary symptoms.